Stenotrophomonas maltophilia in Malaysia: Molecular epidemiology and trimethoprim-sulfamethoxazole resistance

International Journal of Infectious Diseases

Volumn 16, Issue 8, 2012, Pages

  Neela, Vasanthakumari ^a   Rankouhi, Seyedeh Zahra Rouhani ^a   van Belkum, Alex ^b,c   Goering, Richard V ^d   Awang, Rukman ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c BIOMÉRIEUX   (France)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Integrons; Malaysia; Stenotrophomonas maltophilia; Sulfonamide resistance; Trimethoprim sulfamethoxazole

Indexed keywords

CEFTAZIDIME; CLAVULANATE POTASSIUM PLUS TICARCILLIN; COTRIMOXAZOLE; LEVOFLOXACIN; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; DISEASE SURVEILLANCE; DISK DIFFUSION; EPSILOMETER TEST; GENETIC VARIABILITY; GENOTYPE; HOSPITAL INFECTION; INTEGRON; INTENSIVE CARE UNIT; MALAYSIA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; STENOTROPHOMONAS MALTOPHILIA; WARD;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTEGRONS; MALAYSIA; PHYLOGENY; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84864380943     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.04.004     Document Type: Article

References (30)

1. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
2. Köseoĝlu O., Sener B., Gülmez D., Altun B., Gür D. Stenotrophomonas maltophilia as a nosocomial pathogen. New Microbiol 2004, 27:273-279.
3. Micozzi A., Venditti M., Monaco M., Friedrich A., Taglietti F., Santilli S., Martino P. Bacteremia due to Stenotrophomonas maltophilia in patients with hematological malignancies. Clin Infect Dis 2000, 31:705-711.
4. Smit W.J., Boquest A.L., Geddes J.E., Tosolini F.A. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology 1994, 26:321-324.
5. Vartivarian S., Anaissie E., Bodey G., Sprigg H., Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia: implications for therapy. Antimicrob Agents Chemother 1994, 38:624-627.
6. Sader H.S., Jones R.N. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005, 25:95-109.
7. Gulmez D., Hascelik G. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin Microbiol Infect 2005, 11:880-886.
8. Fedler K.A., Biedenbach D.J., Jones R.N. Assessment of pathogen frequency and resistance patterns among paediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on three continents. Diagn Microbiol Infect Dis 2006, 56:427-436.
9. Caylan R., Kaklikkaya N., Aydin K., Aydin F., Yilmaz G., Ozgumus B., et al. An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. Jpn J Infect Dis 2004, 57:37-40.
10. Whitby P.W., Carter K.B., Burns J.L., Royall J.A., LiPuma J.J., Stull T.L. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol 2000, 38:4305-4309.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA: CLSI; 2007.
12. Toleman M.A., Bennett P.M., Walsh T.R. Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons. J Antimicrob Chemother 2006, 58:1-6.
13. Schroeder C.M., Zhao C., DebRoy C., Torcolini J., Zhao S., White D.G., et al. Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Appl Environ Microbiol 2002, 68:576-581.
14. Noguchi N., Suwa J., Narui K., Sasatsu M., Ito T., Hiramatsu K., et al. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol 2005, 54:557-565.
15. Nseir S., Di Pompeo C., Brisson H., Dewavrin F., Tissier S., Diarra M., Boulo M., Durocher A. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Critical Care 2006, 10:1-9.
16. Meyer E., Schwab F., Gastmeier P., Rueden H., Daschner F., Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect 2006, 64:238-243.
17. Nicodemo A., Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229-237.
18. Gesu G.P., Marchetti F., Piccoli L., Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003, 47:816.
19. Toleman M.A., Bennett P.M., Bennett D.M., Jones R.N., Walsh T.R. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 2007, 13:559-565.
20. Gabriel P.S., Zhou J., Tabibi S., Chen Y., Trauzzi M., Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:168-171.
21. Barbolla R., Catalano M., Orman B.E., Famiglietti A., Vay C., Smayevsky J., et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 2004, 48:666-669.
22. Zelenitsky S.A., Iacovides H., Ariano R.E., Harding G.K. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005, 51:39-43.
23. Al-Jasser A.M. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006, 5-23.
24. Chang L.L., Lin H.H., Chang C.Y., Lu P.L. Increased incidence of class 1 integrons in trimethoprim/sulfamethoxazole-resistant clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2007, 59:1038-1039.
25. Liaw S.J., Lee Y.L., Hsueh P.R. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation. Int J Antimicrob Agents 2010, 35:126-130.
26. Smith K., Gemmell C.G., Hunter I.S. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008, 61:78-84.
27. Barchitta M., Cipresso R., Giaquinta L., Romeo M.A., Denaro C., Pennisi C., Agodi A. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health 2009, 212:330-337.
28. Tan C.K., Liaw S.J., Yu C.J., Teng L.J., Hsueh P.R. Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. Diagn Microbiol Infect Dis 2008, 60:205-210.
29. Valdezate S., Vindel A., Martin-Davila P., Del Saz B.S., Baquero F., Canton R. High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol 2004, 42:693-699.
30. Jumaa P.A., Sonnevend A., Pàl T., El Hag M., Amith R., Trad O. The molecular epidemiology of Stenotrophomonas maltophilia bacteraemia in a tertiary referral hospital in the United Arab Emirates 2000-2004. Ann Clin Microbiol Antimicrob 2006, 5:1-6.